ALG 021618
Alternative Names: ALG-021618Latest Information Update: 06 Sep 2022
At a glance
- Originator Aligos Therapeutics
- Class Antisense oligonucleotides; Antivirals
- Mechanism of Action Hepatitis B virus X protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis B